ArticleBrain sciences2021
Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2025Guideline
- Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations.European neurology · 2024Pooled it
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
- Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.Brain sciences · 2025Article
- Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson's Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study.Brain sciences · 2025Article
- The Role of MAO-B Inhibitors in Fatigue in Parkinson's Disease: A Narrative Review.Journal of clinical medicine · 2025Review
- Non-Motor Fluctuations in Parkinson's Disease: Underdiagnosed Yet Important.Journal of movement disorders · 2025Article
- Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review.Frontiers in neurology · 2025Review
- Use of safinamide for treatment of Parkinson disease: real-world data from Spain.Drugs in context · 2025Review
- Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson's disease: a narrative review and expert opinion.Therapeutic advances in neurological disorders · 2025Review
- German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.Journal of neurology · 2024Article
- Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.Revista de neurologia · 2023Article
- Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.Brain sciences · 2023Review
- Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.Patient related outcome measures · 2023Review
- An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.Current neuropharmacology · 2023Review
- Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.NPJ Parkinson's disease · 2022Article
- Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study.Diagnostics (Basel, Switzerland) · 2022Article
- Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.Brain sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some studies observed a benefit of Parkinson's disease (PD) patients after treatment with safinamide in some non-motor symptoms (NMSs). The aim of this study was to analyze the effectiveness of safinamide on NMS burden in PD. SAFINONMOTOR (an open-label study of the effectiveness of safinamide on non-motor symptoms in Parkinson's disease patients) is a prospective open-label single-arm study conducted in five centers from Spain. The primary efficacy outcome was the change from baseline (V1) to the end of the observational period (6 months) (V4) in the non-motor symptoms scale (NMSS) total score. Between May/2019 and February/2020 50 patients were included (age 68.5 ± 9.12 years; 58% females; 6.4 ± 5.1 years from diagnosis). At 6 months, 44 patients completed the follow-up (88%). The NMSS total score was reduced by 38.5% (from 97.5 ± 43.7 in V1 to 59.9 ± 35.5 in V4;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.